Welcome! If you have a coupon code, click here to apply it. Apply
stock
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ | NAMS
18.37
USD
0.00 (0.00%)
AT CLOSE (AS OF May 9, 2025)
$2.2B
MARKET CAP
-
P/E Ratio
-2.56
EPS
$27
52 Week High
$14
52 Week Low
LIFE SCIENCES
Sector
NAMS Chart
Price Action Signals for NAMS
Trade Smarter
Automate your trading workflow with powerful tools — built for serious traders.
NAMS Technicals
NAMS Earnings
Yearly Income Statement (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Gross Profit | $45M |
| Total Revenue | $46M |
| Cost Of Revenue | $113K |
| Costof Goods And Services Sold | $113K |
| Operating Income | -$176M |
| Selling General And Administrative | $70M |
| Research And Development | $151M |
| Operating Expenses | $222M |
| Investment Income Net | - |
| Net Interest Income | $17M |
| Interest Income | $17M |
| Interest Expense | $0 |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $113K |
| Income Before Tax | -$242M |
| Income Tax Expense | -$1K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$242M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$242M |
| Ebitda | -$241M |
| Net Income | -$242M |
Revenue & Profitability
Earnings Performance
Actual: $undefined
Estimate: $undefined
Difference: $undefined
Period Qundefined
NAMS Financials
yearly Balance Sheet (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Total Assets | $865M |
| Total Current Assets | $863M |
| Cash And Cash Equivalents At Carrying Value | $772M |
| Cash And Short Term Investments | $772M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $1.2M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $534K |
| Intangible Assets Excluding Goodwill | $534K |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $62M |
| Other Current Assets | $29M |
| Other Non Current Assets | - |
| Total Liabilities | $107M |
| Total Current Liabilities | $107M |
| Current Accounts Payable | $4.7M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $246K |
| Total Non Current Liabilities | $202K |
| Capital Lease Obligations | $448K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $448K |
| Other Current Liabilities | $96M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $758M |
| Treasury Stock | - |
| Retained Earnings | -$559M |
| Common Stock | $13M |
| Common Stock Shares Outstanding | $94M |
yearly Cash Flow (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$159M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $113K |
| Capital Expenditures | $672K |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | - |
| Cashflow From Financing | $660M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$242M |
yearly Income Statement (As of Dec 31, 2024)
| Field | Value (USD) |
|---|---|
| Gross Profit | $45M |
| Total Revenue | $46M |
| Cost Of Revenue | $113K |
| Costof Goods And Services Sold | $113K |
| Operating Income | -$176M |
| Selling General And Administrative | $70M |
| Research And Development | $151M |
| Operating Expenses | $222M |
| Investment Income Net | - |
| Net Interest Income | $17M |
| Interest Income | $17M |
| Interest Expense | $0 |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $113K |
| Income Before Tax | -$242M |
| Income Tax Expense | -$1K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$242M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$242M |
| Ebitda | -$241M |
| Net Income | -$242M |
NAMS News
News Sentiment
The news sentiment chart shows the sentiment of news articles related to the symbol.
NewAmsterdam Pharma Company N.V. Ordinary Shares Top Stories
NewAmsterdam Pharma Company N.V. ( NAMS ) Reports Q1 Loss, Tops Revenue Estimates - 8 May 2025
Akebia Therapeutics ( AKBA ) Q1 Earnings and Revenues Top Estimates - 8 May 2025
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - 8 May 2025
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society ( EAS ) Congress 2025 - 7 May 2025
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - NewAmsterdam Pharma Co ( NASDAQ:NAMSW ) , NewAmsterdam Pharma Co ( NASDAQ:NAMS ) - 2 May 2025
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 4 April 2025
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference - NewAmsterdam Pharma Co ( NASDAQ:NAMSW ) , NewAmsterdam Pharma Co ( NASDAQ:NAMS ) - 31 March 2025
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Agilon Health ( NYSE:AGL ) , Accel Entertainment ( NYSE:ACEL ) - 26 February 2025
Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Acadian Asset Management ( NYSE:AAMI ) , Accel Entertainment ( NYSE:ACEL ) - 26 February 2025
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 7 February 2025
NewAmsterdam Pharma to Present at Guggenheim's SMID Cap Biotech Conference - NewAmsterdam Pharma ( NASDAQ:NAMSW ) , NewAmsterdam Pharma ( NASDAQ:NAMS ) - 29 January 2025
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - C&F Financial ( NASDAQ:CFFI ) , ANI Pharmaceuticals ( NASDAQ:ANIP ) - 16 January 2025
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities - NewAmsterdam Pharma ( NASDAQ:NAMSW ) , NewAmsterdam Pharma ( NASDAQ:NAMS ) - 10 January 2025
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 9 January 2025
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - NewAmsterdam Pharma ( NASDAQ:NAMSW ) , NewAmsterdam Pharma ( NASDAQ:NAMS ) - 13 December 2024
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares - 13 December 2024
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - 12 December 2024
Top 3 Health Care Stocks That May Collapse This Quarter - Paragon 28 ( NYSE:FNA ) , Adaptive Biotechnologies ( NASDAQ:ADPT ) - 11 December 2024
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - NewAmsterdam Pharma ( NASDAQ:NAMSW ) , NewAmsterdam Pharma ( NASDAQ:NAMS ) - 10 December 2024
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - 10 December 2024
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - NewAmsterdam Pharma ( NASDAQ:NAMS ) - 10 December 2024
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday - Alaska Air Gr ( NYSE:ALK ) , Absci ( NASDAQ:ABSI ) - 10 December 2024
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia - 10 December 2024
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia - NewAmsterdam Pharma ( NASDAQ:NAMSW ) , NewAmsterdam Pharma ( NASDAQ:NAMS ) - 10 December 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 6 December 2024
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH - NewAmsterdam Pharma ( NASDAQ:NAMSW ) , NewAmsterdam Pharma ( NASDAQ:NAMS ) - 20 November 2024
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024 - 18 November 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 1 November 2024
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - 28 October 2024
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November - NewAmsterdam Pharma ( NASDAQ:NAMSW ) , NewAmsterdam Pharma ( NASDAQ:NAMS ) - 28 October 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 4 October 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 6 September 2024
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - 30 August 2024
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - NewAmsterdam Pharma ( NASDAQ:NAMSW ) , NewAmsterdam Pharma ( NASDAQ:NAMS ) - 30 August 2024
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - NewAmsterdam Pharma ( NASDAQ:NAMS ) - 28 August 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 2 August 2024
Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results - NewAmsterdam Pharma ( NASDAQ:NAMS ) - 30 July 2024
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Pearson ( NYSE:PSO ) - 29 July 2024
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 - 26 July 2024
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors - 8 July 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 3 July 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 7 June 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - 3 May 2024
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 - NewAmsterdam Pharma ( NASDAQ:NAMSW ) , NewAmsterdam Pharma ( NASDAQ:NAMS ) - 2 May 2024
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer - 1 April 2024
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress - NewAmsterdam Pharma ( NASDAQ:NAMS ) , NewAmsterdam Pharma ( NASDAQ:NAMSW ) - 25 March 2024
NewAmsterdam ( NAMS ) Doses Patient in HeFH Study, Shares Up - 13 March 2024
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - 14 February 2024
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - NewAmsterdam Pharma ( NASDAQ:NAMSW ) , NewAmsterdam Pharma ( NASDAQ:NAMS ) - 14 February 2024
World Acceptance Posts Upbeat Earnings, Joins Kaman, Spirit Airlines And Other Big Stocks Moving Higher On Friday - World Acceptance ( NASDAQ:WRLD ) - 19 January 2024
NAMS Profile
NewAmsterdam Pharma Company N.V. Ordinary Shares Profile
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
None
LGMK 31.53%
$0.0146
GNLN 19.67%
$0.0073
NVVE 143.86%
$2.78
ITP 60.90%
$0.4362
SHPH -13.89%
$0.2325
NXTT 661.29%
$2.36
QBTS 6.43%
$11.09
LCID 8.66%
$2.51
NCNA -59.18%
$0.042
NVDA -0.61%
$116.65
TSLA 4.72%
$298.26
IOVA -44.80%
$1.75
LYFT 28.08%
$16.65
DGLY -29.07%
$0.0427
SRXH
29.79%
$0.6879
MARA 10.29%
$15.76
NVNI -0.38%
$0.531
PLTR -1.55%
$117.3
PLUG 1.19%
$0.8605
F 1.46%
$10.43
NITO 16.95%
$0.4444
ZAPP 29.16%
$0.4004
ITUB 6.19%
$6.605
HIMS 1.15%
$51.99
BBD 0.74%
$2.72
AAL 0.73%
$11.11
RGTI 2.62%
$10.58
BTG 3.97%
$3.14
PTPI -4.23%
$0.1201
LYT -16.78%
$0.0982
ASST 5.59%
$8.12
SOFI -0.60%
$13.18
BB 0.26%
$3.81
RIVN 4.24%
$14.26
CLSK 5.99%
$9.2
INTC 2.00%
$21.42
TTD 18.60%
$71.04
ILAG 31.13%
$0.505
ZKIN 58.33%
$3.99
CAN 14.89%
$0.7486
HOOD 1.07%
$54.65
PINS 4.88%
$29.22
LYG 0.39%
$3.885
SOUN -7.80%
$8.98
DNN 1.32%
$1.54
WULF -8.79%
$3.01
BTE 3.48%
$1.635
PFE -3.00%
$22.28
RIG 4.60%
$2.615
DEVS -18.70%
$0.326
AAPL 0.53%
$198.53
TAOP -18.84%
$0.1637
CLF -2.17%
$6.995
RIOT 0.47%
$8.48
GOOGL -0.99%
$152.75
AFRM -14.47%
$46.41
DNUT -16.26%
$2.73
WORX 10.58%
$0.606
AMD 1.12%
$102.84
SMCI -0.37%
$31.99
COMP -19.15%
$6.25
RKLB -11.21%
$20.51
WBD 0.67%
$9.07
CDE 12.48%
$7.84
RUN 10.35%
$9.38
ME -21.26%
$0.6063
CUTR -10.19%
$0.0969
AMZN 0.51%
$193.06
HL 4.67%
$5.15
VRN 0.33%
$6.03
SNAP 0.36%
$8.25
DKNG 2.49%
$36.23
BAC 0.47%
$41.795
T 1.35%
$27.84
AGMH -0.31%
$0.0977
AQN 9.62%
$5.985
AGNC -1.01%
$8.79
ERIC 0.12%
$8.29
NGD 3.98%
$4.18
APLD -2.00%
$5.39
FUBO -0.19%
$2.695
KVUE 1.66%
$24.46
NIO 0.13%
$3.965
TOST 11.41%
$40.83
WBUY 59.21%
$11.32
PTON -5.38%
$6.16
PRMB -1.24%
$31.92
GRAB -0.61%
$4.9
GOOG -0.88%
$154.38
AG 7.08%
$5.9
MCHP 12.60%
$55.33
PBR 1.29%
$11.8
MULN -6.40%
$0.2268
CIFR -4.49%
$2.98
FSM 6.25%
$5.695
NVAX -10.29%
$5.975
BTBT 0.00%
$2.08
VALE 0.70%
$9.365
ABEV -0.20%
$2.525
BP 4.13%
$29.77
LGMK 31.53%
$0.0146
GNLN 19.67%
$0.0073
NVVE 143.86%
$2.78
ITP 60.90%
$0.4362
SHPH -13.89%
$0.2325
NXTT 661.29%
$2.36
QBTS 6.43%
$11.09
LCID 8.66%
$2.51
NCNA -59.18%
$0.042
NVDA -0.61%
$116.65
TSLA 4.72%
$298.26
IOVA -44.80%
$1.75
LYFT 28.08%
$16.65
DGLY -29.07%
$0.0427
SRXH
29.79%
$0.6879
MARA 10.29%
$15.76
NVNI -0.38%
$0.531
PLTR -1.55%
$117.3
PLUG 1.19%
$0.8605
F 1.46%
$10.43
NITO 16.95%
$0.4444
ZAPP 29.16%
$0.4004
ITUB 6.19%
$6.605
HIMS 1.15%
$51.99
BBD 0.74%
$2.72
AAL 0.73%
$11.11
RGTI 2.62%
$10.58
BTG 3.97%
$3.14
PTPI -4.23%
$0.1201
LYT -16.78%
$0.0982
ASST 5.59%
$8.12
SOFI -0.60%
$13.18
BB 0.26%
$3.81
RIVN 4.24%
$14.26
CLSK 5.99%
$9.2
INTC 2.00%
$21.42
TTD 18.60%
$71.04
ILAG 31.13%
$0.505
ZKIN 58.33%
$3.99
CAN 14.89%
$0.7486
HOOD 1.07%
$54.65
PINS 4.88%
$29.22
LYG 0.39%
$3.885
SOUN -7.80%
$8.98
DNN 1.32%
$1.54
WULF -8.79%
$3.01
BTE 3.48%
$1.635
PFE -3.00%
$22.28
RIG 4.60%
$2.615
DEVS -18.70%
$0.326
AAPL 0.53%
$198.53
TAOP -18.84%
$0.1637
CLF -2.17%
$6.995
RIOT 0.47%
$8.48
GOOGL -0.99%
$152.75
AFRM -14.47%
$46.41
DNUT -16.26%
$2.73
WORX 10.58%
$0.606
AMD 1.12%
$102.84
SMCI -0.37%
$31.99
COMP -19.15%
$6.25
RKLB -11.21%
$20.51
WBD 0.67%
$9.07
CDE 12.48%
$7.84
RUN 10.35%
$9.38
ME -21.26%
$0.6063
CUTR -10.19%
$0.0969
AMZN 0.51%
$193.06
HL 4.67%
$5.15
VRN 0.33%
$6.03
SNAP 0.36%
$8.25
DKNG 2.49%
$36.23
BAC 0.47%
$41.795
T 1.35%
$27.84
AGMH -0.31%
$0.0977
AQN 9.62%
$5.985
AGNC -1.01%
$8.79
ERIC 0.12%
$8.29
NGD 3.98%
$4.18
APLD -2.00%
$5.39
FUBO -0.19%
$2.695
KVUE 1.66%
$24.46
NIO 0.13%
$3.965
TOST 11.41%
$40.83
WBUY 59.21%
$11.32
PTON -5.38%
$6.16
PRMB -1.24%
$31.92
GRAB -0.61%
$4.9
GOOG -0.88%
$154.38
AG 7.08%
$5.9
MCHP 12.60%
$55.33
PBR 1.29%
$11.8
MULN -6.40%
$0.2268
CIFR -4.49%
$2.98
FSM 6.25%
$5.695
NVAX -10.29%
$5.975
BTBT 0.00%
$2.08
VALE 0.70%
$9.365
ABEV -0.20%
$2.525
BP 4.13%
$29.77
Discover more tools and features to empower your trading
Explore FeaturesQuotes and other market data may be delayed by 15 minutes or more. Financial data is provided by financial exchanges and other content providers and may be delayed as specified by financial exchanges or other data providers. AfterPullback does not verify any data and disclaims any obligation to do so. The information contained on this website is not intended as, and shall not be understood as, financial advice. The website does not operated by attorney, accountant or financial advisor and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation. Nothing available on or through this website should be understood as a recommendation that you should not consult with a financial professional to address your particular information.
You have a coupon!
We've successfully recognized your coupon code. You can visit the pricing page to use it or feel free to look around first.